Introduction
============

Cancer, caused by complex factors including genetics and environment, as well as by the interactions between these two factors, is a severe global public-health problem.[@b1-ott-9-899],[@b2-ott-9-899] DNA damage may lead to human cancer, while DNA repair pathways such as mismatch repair (MMR) in mammals may play a role in repairing such damage.[@b3-ott-9-899],[@b4-ott-9-899] Genetic variations in DNA repair genes may influence repair efficiency and alter cancer risks.[@b5-ott-9-899]

The exonuclease 1 (*Exo1*) gene, belonging to the MMR system and the RAD2/XPG nuclease family, encodes an 846 amino acid protein, which functions in DNA repair, replication, and homologous recombination.[@b6-ott-9-899]--[@b9-ott-9-899] Exo1 can interact physically with the MMR proteins MLH1 and MSH2 and participate in mismatch-provoked excision repair by forming a ternary complex of Exo1-MLH1-PMS2 or Exo1-MSH2-MSH6.[@b10-ott-9-899]--[@b12-ott-9-899]

Several nonsynonymous coding polymorphisms in the *Exo1* gene have been identified. These polymorphisms may lead to amino acid changes and may affect the interactions between the Exo1 protein and other MMR proteins, resulting in altered DNA repair capacity and influencing cancer risks.[@b13-ott-9-899],[@b14-ott-9-899] In consideration of the possible influence of the genetic variants on the repair efficiency of the MMR system and cancer susceptibilities, many studies have assessed the relationship between *Exo1* polymorphisms and cancer risks.

To date, three single-nucleotide polymorphisms (SNPs) of the *Exo1* gene -- Pro757Leu (rs9350, C/T) at exon 13, Glu589Lys (rs1047840, G/A), and Glu670Gly (rs1776148, A/G) at exon 11 -- have been the most widely investigated in epidemiological studies.[@b15-ott-9-899]--[@b30-ott-9-899] Not all of these studies, however, reached the same conclusion, which may be partly due to the limitations of individual studies. Therefore, we carried out this meta-analysis of all eligible case-control studies to draw a more reliable conclusion of the association between *Exo1* polymorphisms (Glu589Lys, Pro757Leu, and Glu670Gly) and cancer susceptibility.

Materials and methods
=====================

Study identification and inclusion criteria
-------------------------------------------

We searched the PubMed and EMBASE databases for relevant studies (last search was updated on August 5, 2015). Without applying search filters, the following keywords were used for the literature search: (Exo1 or "Exonuclease 1"), (cancer or carcinoma or tumor or neoplasm), and (polymorphism or variant or variation or mutation). Furthermore, the references in the retrieved articles were also manually screened to ensure that no relevant publication was missed.

All studies used in our meta-analysis were carefully examined to meet the following criteria: case--control studies conducted on human subjects, with full text articles that investigated the association between cancer risk and at least one of three *Exo1* gene polymorphisms (Pro757Leu, Glu589Lys, or Glu670Gly). Another requirement of these studies was the inclusion of an odds ratio (OR) with 95% confidence intervals (CIs) or the provision of sufficient raw data to calculate these measures. A request letter for the original genotype frequency data was sent to the corresponding author when such data were unavailable in relevant articles. If studies had overlapping data, only the more complete study was used.

Data extraction
---------------

Two investigators collected the following items from each eligible study, independently: name of the first author, year of publication, ethnicity, country, cancer types, genotyping method, source of controls, numbers of cases and controls, genotype frequency of cases and controls, and the demographic data -- if available -- including smoking status.

Statistical analysis
--------------------

This meta-analysis was performed for a recessive model (aa vs Aa+AA, where "A" was the major allele and "a" was the minor allele), dominant model (aa+Aa vs AA), homozygote comparison (aa vs AA), heterozygote comparison (Aa vs AA), and additive model (a vs A). We used ORs with 95% CIs to evaluate the strength of association between *Exo1* polymorphisms and cancer risk, while pooled ORs were obtained by calculating a weighted average of OR from each study.[@b31-ott-9-899] Between-study heterogeneity, measured by a *Q*-statistic test[@b32-ott-9-899] and *I*^2^ statistic,[@b33-ott-9-899] was assessed to determine whether a fixed-effects or random-effects model should be applied. When the *P*~h~ value of the *Q*-test is smaller than 0.05, which indicated a significant heterogeneity among the studies, a random-effects model[@b34-ott-9-899] was used to calculate the pooled ORs; otherwise the fixed-effects model[@b35-ott-9-899] was used.

Subgroup analyses were performed by ethnicity, source of controls, cancer types, and smoking status to explore the effect of heterogeneity among the studies. Univariate meta-regression analysis was used to further clarify the potential reasons for heterogeneity (*P*\<0.05 was considered significant).[@b36-ott-9-899] Studies were split into large sample size or small sample size using the cut-point of 600 participants. By sequentially omitting each study, sensitivity analysis was used to assess the stability of the results. Begg's funnel plot and Egger's linear regression test were carried out to estimate the potential publication bias, graphically and statistically, and *P*\<0.05 was considered significant.[@b37-ott-9-899]

A goodness-of-fit *χ*^2^ test with 1 degree of freedom was applied to assess the Hardy--Weinberg equilibrium (HWE) in controls and a value of *P*\<0.05 was considered as a significant disequilibrium. We used the software program STATA (version 12.0; StataCorp LP, College Station, TX, USA) for all the statistical analyses in this meta-analysis.

Results
=======

Extraction process and study characteristics
--------------------------------------------

On the basis of the inclusion criteria, 17 publications were preliminarily identified as eligible.[@b15-ott-9-899]--[@b30-ott-9-899],[@b38-ott-9-899] Among these, the study conducted by Yoshiya et al[@b38-ott-9-899] was excluded because the data were the same as those for the earlier study by Yamamoto et al.[@b15-ott-9-899] Thus, 16 articles were included in the final meta-analysis.[@b15-ott-9-899]--[@b30-ott-9-899] [Table 1](#t1-ott-9-899){ref-type="table"} summarizes the main characteristics of the selected studies, while [Figure 1](#f1-ott-9-899){ref-type="fig"} shows the study selection process. The genotyping data in the study by Jin et al[@b19-ott-9-899] were only analyzed in the additive genetic model because the data were limited. In addition, the data from Tang et al's study[@b30-ott-9-899] were genome-wide association study data. In the pooled analyses, we included 4,093 cases and 3,834 controls from 10 studies for the Pro757Leu polymorphism, 6,479 cases and 6,550 controls from 12 studies for the Glu589Lys polymorphism, and 3,700 cases and 3,496 controls from 7 studies for the Glu670Gly polymorphism. Of these, six were studies of Caucasians, nine were studies of Asians, and one was a study of mixed population, while four were population based and ten were hospital based. In addition, there were three lung cancer studies,[@b16-ott-9-899],[@b19-ott-9-899],[@b21-ott-9-899] four colorectal cancer studies,[@b15-ott-9-899],[@b17-ott-9-899],[@b25-ott-9-899],[@b29-ott-9-899] two cervical cancer studies,[@b24-ott-9-899],[@b28-ott-9-899] and seven others studies including glioblastoma,[@b18-ott-9-899] gastric cancer,[@b20-ott-9-899] oral cancer,[@b22-ott-9-899] breast cancer,[@b23-ott-9-899] melanoma,[@b26-ott-9-899] hepatocellular cancer,[@b27-ott-9-899] and pancreatic cancer.[@b30-ott-9-899] [Table 2](#t2-ott-9-899){ref-type="table"} lists the genotype distribution and allele frequency of *Exo1* polymorphism among cancer cases and controls and the *P*-value of the HWE in the controls.

Meta-analysis results
---------------------

The main results for the three *Exo1* polymorphisms of this meta-analysis are listed in [Table 3](#t3-ott-9-899){ref-type="table"}. Overall, the combined results based on all eligible studies showed a significant association between the Pro757Leu polymorphism and reduced cancer risk (dominant model: OR =0.902, 95% CI =0.821--0.991, *P*=0.032; and heterozygote comparison: OR =0.894, 95% CI =0.809--0.988, *P*=0.027; [Table 3](#t3-ott-9-899){ref-type="table"}). Moreover, in the stratified analysis, the results showed that the Pro757Leu polymorphism was associated with a reduced risk of cancer among Asians (dominant model: OR =0.852, 95% CI =0.765--0.949, *P*=0.004; heterozygote comparison: OR =0.847, 95% CI =0.755--0.951, *P*=0.005; and additive model: OR =0.932, 95% CI =0.871--0.997, *P*=0.039; [Figure 2](#f2-ott-9-899){ref-type="fig"}), but not among Caucasians. In the subgroup analysis by source of controls, a significant association was found between the Pro757Leu polymorphism and a reduced cancer risk in the dominant model and in the heterozygote comparison in the hospital-based controls (Leu/Leu+Pro/Leu vs Pro/Pro: OR =0.882, 95% CI =0.797--0.977, *P*=0.016; Pro/Leu vs Pro/Pro: OR =0.878, 95% CI =0.788--0.979, *P*=0.019; [Table 3](#t3-ott-9-899){ref-type="table"}), but not in the population-based controls. Moreover, the Leu allele of the Pro757Leu polymorphism was significantly associated with a reduced risk of colorectal cancer (dominant model: OR =0.724, 95% CI =0.557--0.942, *P*=0.016; homozygote comparison: OR =0.633, 95% CI =0.417--0.961, *P*=0.032; and additive model: OR =0.782, 95% CI =0.648--0.943, *P*=0.010).

In terms of the *Exo1* Glu589Lys polymorphism, a statistically significant association was found between the *Exo1* Glu589Lys polymorphism and the risk of cancer in the homozygote comparison (Lys/Lys vs Glu/Glu: OR =1.447, 95% CI =1.028--2.035, *P*=0.034) and in the additive model (Lys vs Glu: OR =1.200, 95% CI =1.014--1.421, *P*=0.034) in the pooled analyses. For Asians, the results showed that the Glu589Lys polymorphism increased the cancer risk (recessive model: OR =1.876, 95% CI =1.444--2.436, *P*\<0.001; dominant model: OR =1.555, 95% CI =1.401--1.726, *P*\<0.001; homozygote comparison: OR =2.133, 95% CI =1.639--2.777, *P*\<0.001; heterozygote comparison: OR =1.495, 95% CI =1.341--1.666, *P*\<0.001; and additive model: OR =1.487, 95% CI =1.361--1.625, *P*\<0.001), while no association was found among Caucasians. When stratified by the source of controls, a significantly elevated cancer risk was found among studies with hospital-based controls (recessive model: OR =1.683, 95% CI =1.097--2.581, *P*=0.017; dominant model: OR =1.405, 95% CI =1.180--1.674, *P*\<0.001; homozygote comparison: OR =1.848, 95% CI =1.164--2.934, *P*=0.009; heterozygote comparison: OR =1.356, 95% CI =1.161--1.583, *P*\<0.001; and additive model: OR =1.366, 95% CI =1.144--1.632, *P*=0.001), while in population-based studies, the results showed that the Glu589Lys polymorphism was associated with a reduced cancer risk only in the heterozygote comparison (OR =0.616, 95% CI =0.453--0.836, *P*=0.002). In terms of cancer types, no association was found for lung cancer. Furthermore, subgroup analysis was also performed by smoking status. The results showed that the Glu589Lys polymorphism was significantly associated with an increased cancer risk in smokers (dominant model: OR =1.866, 95% CI =1.384--2.515, *P*\<0.001; [Table 4](#t4-ott-9-899){ref-type="table"}, [Figure 3](#f3-ott-9-899){ref-type="fig"}), but not in nonsmokers.

In terms of the *Exo1* Glu670Gly polymorphism, no evidence was found for an association between the Glu670Gly polymorphism and cancer risk for all genetic models ([Table 3](#t3-ott-9-899){ref-type="table"}). Furthermore, the results in the subgroup analyses by ethnicity, source of controls, and cancer types revealed no association, either.

Test of heterogeneity
---------------------

The heterogeneity test showed that no significant heterogeneity was found for the Pro757Leu and Glu670Gly polymorphisms in all comparisons ([Table 3](#t3-ott-9-899){ref-type="table"}). However, there was significant between-study heterogeneity for the *Exo1* Glu589Lys polymorphism in all genetic models ([Table 3](#t3-ott-9-899){ref-type="table"}). Subgroup analysis was performed to explore the potential sources of heterogeneity. After patients were stratified by ethnicity, no heterogeneity was found in the Asian population, which indicated that ethnicity may contribute to substantial heterogeneity for the Glu589Lys polymorphism. A series of univariate meta-regression analyses under all genetic models, with the covariates of ethnicity, publication year, sample size, and HWE, showed that only ethnicity had a significant influence on heterogeneity (recessive model: *P*=0.029; dominant model: *P*=0.035; homozygote comparison: *P*=0.032; and additive model: *P*=0.004; [Table 5](#t5-ott-9-899){ref-type="table"}).

Sensitivity analysis
--------------------

Sensitivity analysis was performed to assess the influence of each individual study on the pooled ORs. The results showed that the conclusions of this meta-analysis for the Glu670Gly polymorphism were relatively stable and credible because the overall ORs were not influenced excessively by omitting any single study (data not shown). However, the conclusions for the Pro757Leu and Glu589Lys polymorphism were not sufficiently stable. While excluding any one of the three studies,[@b17-ott-9-899],[@b22-ott-9-899],[@b23-ott-9-899] the pooled ORs for the Pro757Leu polymorphism changed and the result became negative in all genetic models, indicating that the results were relatively unstable. In terms of the Glu589Lys polymorphism, when the study by Chang et al[@b18-ott-9-899] was excluded, the association between the *Exo1* Glu589Lys polymorphism and the risk of cancer became significant in all genetic models (recessive model: OR =1.399, 95% CI =1.048--1.866, *P*=0.022; dominant model: OR =1.333, 95% CI =1.086--1.637, *P*=0.006; homozygote comparison: OR =1.601, 95% CI =1.144--2.240, *P*=0.006; heterozygote comparison: OR =1.294, 95% CI =1.055--1.587, *P*=0.013; and additive model: OR =1.269, 95% CI =1.079--1.494, *P*=0.004), suggesting that this study significantly influenced the result.

Publication bias
----------------

The publication bias of the literature was assessed by both Begg's funnel plot and Egger's test. The shapes of the funnel plots for each polymorphism showed no obvious asymmetry ([Figure 4](#f4-ott-9-899){ref-type="fig"}). Evidence of publication bias was not found using Egger's test for the Pro757Leu polymorphism (recessive model: *P*=0.188; dominant model: *P*=0.357; homozygote comparison: *P*=0.188; heterozygote comparison: *P*=0.734; and additive model: *P*=0.178), Glu589Lys polymorphism (recessive model: *P*=0.093; dominant model: *P*=0.516; homozygote comparison: *P*=0.081; heterozygote comparison: *P*=0.556; and additive model: *P*=0.310), and Glu670Gly polymorphism (recessive model: *P*=0.679; dominant model: *P*=0.193; homozygote comparison: *P*=0.608; heterozygote comparison: *P*=0.098; and additive model: *P*=0.666), respectively.

Discussion
==========

Our meta-analysis is the first study to investigate the association between *Exo1* Pro757Leu and Glu670Gly polymorphisms of Exo1 and cancer susceptibility, and also the largest and most comprehensive assessment of the relationship between the Glu589Lys polymorphism and cancer risk. In our study, we conducted an analysis that included 10 studies relating to the Pro757Leu polymorphism (4,093 cases and 3,834 controls), 12 studies relating to the Glu589Lys polymorphism (6,479 cases and 6,550 controls), and 7 studies relating to the Glu670Gly polymorphism (3,700 cases and 3,496 controls). The final results showed that Pro757Leu conferred a protective effect against cancer, and the Glu589Lys polymorphism was associated with an increased cancer risk, but the Glu670Gly polymorphism was not statistically significantly associated with cancer risk. Interestingly, stratified analysis by ethnicity indicated that, among Asians, the Pro757Leu polymorphism was associated with a reduced risk of cancer under the dominant model, heterozygote comparison, and additive model, whereas the Glu589Lys polymorphism was significantly associated with increased cancer risk under all the genetic models. The differences between Asians and other races may be partly due to the different genetic backgrounds and environments or lifestyles.[@b39-ott-9-899] The Leu allele frequency of the Pro757Leu polymorphism among the controls in the Asian population was 43.7% (95% CI =42.5%--44.8%), which was significantly higher than that in the Caucasian population (14.7%, 95% CI =12.2%--17.1%, *P*\<0.001). On the contrary, the Lys and Gly allele frequency of the Glu589Lys and Glu670Gly polymorphisms in Asians was 16.3% (95% CI =15.4%--17.2%) and 15.3% (95% CI =14.3%--16.2%), which was significantly lower than that in Caucasians (38.3%, 95% CI =37.1%--39.5%, *P*\<0.001, and 35.7%, 95% CI =32.7%--38.7%, *P*\<0.001). In subgroup analysis of the different sources of controls, significant associations were found between the Pro757Leu polymorphism and reduced cancer risk, while evidence of an association between the Glu589Lys polymorphism and an increased cancer risk was found in the hospital-based studies, but not in the population-based studies. This may be because the hospital-based controls may have sickness that was connected with the genotypes under investigation, leading to potential biases.[@b40-ott-9-899] Furthermore, there was a significantly negative correlation between the Leu allele of the Pro757Leu polymorphism and colorectal cancer risk. However, this result should be interpreted with caution because only three studies (728 cases and 768 controls) were included in the analysis. Moreover, subgroup analysis was also performed under smoking conditions for the Glu589Lys polymorphism. The results showed that the Glu589Lys polymorphism was significantly associated with an increased cancer risk in smokers, but not in nonsmokers, which indicated that cigarette smoking can cause DNA damage and influence the DNA repair activity, which then alters the cancer risk. There was no evidence for an association between the Glu670Gly polymorphism and cancer risk in subgroup analyses based on ethnicity, source of controls, and cancer types. In the future, larger well-designed studies will be needed to validate these associations.

In this study, there was significant heterogeneity between studies relating to the Glu589Lys polymorphism, but not to the other two polymorphisms. To explore the sources of heterogeneity, studies were classified according to ethnicity, source of controls, cancer type, and sample size. The results showed that the heterogeneity was significantly reduced in the Asian population subgroup, which indicated that ethnicity could partly explain the source of heterogeneity. The studies for the Caucasian population yielded different results, with high heterogeneity, revealing the necessity for further study. Likewise, the metaregression analysis identified ethnicity as an important contributor to heterogeneity. Furthermore, the sensitivity analysis showed that the study by Chang et al[@b18-ott-9-899] could have an influence on the overall results for Glu589Lys polymorphism because it was the only study to reveal that the Glu589Lys polymorphism was significantly related to reduced cancer risk. Although the three studies by Kim et al,[@b17-ott-9-899] Tsai et al,[@b22-ott-9-899] and Wang et al[@b23-ott-9-899] may affect the overall results for the Pro757Leu polymorphism, none of the studies led to a change in conclusions for the Asian population, indicating that the results for the Asian population were relatively stable and credible. Additionally, the overall results for the Pro757Leu and Glu589Lys polymorphisms were dominated by the conclusions for the Asian population, which indicated that ethnicity was an important factor in Exo1 SNPs and should be carefully considered in future studies.

Many previous studies have investigated the association between the Pro757Leu polymorphism and cancer risk. Studies performed by Yamamoto et al,[@b15-ott-9-899] Kim et al,[@b17-ott-9-899] and Haghighi et al[@b25-ott-9-899] revealed that the Leu/Leu genotype is associated with reduced risk of colorectal cancer in Asians, which concurred with our results of subgroup analysis on ethnicity and cancer types. However, the results of some studies differ from our own results,[@b19-ott-9-899]--[@b22-ott-9-899] which may be attributed to the limitation of sample size. Similarly, in terms of the Glu589Lys polymorphism, the studies for the Asian population uniformly showed that individuals with the Glu/Lys or Lys/Lys genotypes had a significantly increased cancer risk, including an increased risk of lung, gastric, breast, oral, and cervical cancer, which concurred with our own conclusion.[@b19-ott-9-899]--[@b23-ott-9-899],[@b28-ott-9-899] Moreover, some other studies found no statistical association between the Glu589Lys polymorphism and cancer risk in the Caucasian population, which was also in line with our own results for Caucasians.[@b16-ott-9-899],[@b26-ott-9-899],[@b30-ott-9-899] In terms of the Glu670Gly polymorphism, we found no significant association with cancer risk, which was consistent with the results of previous studies.[@b18-ott-9-899]--[@b23-ott-9-899],[@b26-ott-9-899]

Interestingly, Bayram[@b41-ott-9-899] and Duan et al[@b42-ott-9-899] have conducted meta-analyses to identify whether there was any evidence of a relationship between the *Exo1* Glu589Lys polymorphism and cancer susceptibility. Their conclusions could be considered to be inconsistent, which may be partially attributable to the relatively small sample size. The meta-analysis by Bayram[@b41-ott-9-899] showed that the Glu589Lys polymorphism was not associated with overall cancer susceptibility, which contrasted with our own results. However, we found that the data reported by Bayram[@b41-ott-9-899] from the studies by Wang et al[@b23-ott-9-899] and Ibarrola-Villava et al[@b26-ott-9-899] were not the same as the original data. Another recent meta-analysis by Duan et al[@b42-ott-9-899] concluded that the Glu589Lys polymorphism was significantly associated with increased cancer risk in all genetic models, which differed from our own results. This may be explained by the relatively small sample size. At least four eligible studies[@b16-ott-9-899],[@b26-ott-9-899],[@b29-ott-9-899],[@b30-ott-9-899] were not included in the meta-analysis by Duan et al,[@b42-ott-9-899] while the study by Jin et al[@b19-ott-9-899] was excluded because their controls deviated from the HWE. Compared with the previous study, five additional studies[@b16-ott-9-899],[@b19-ott-9-899],[@b26-ott-9-899],[@b29-ott-9-899],[@b30-ott-9-899] -- with 3,528 cases and 3,449 controls in total -- were included in our meta-analysis, from which more solid evidence could be provided on the association between the Glu589Lys polymorphism and cancer risk.

Some limitations of our meta-analysis should also be considered when interpreting the results. First, there was an insufficient number of studies collected in this analysis to explore a true association between *Exo1* polymorphisms and cancer risk, especially in terms of the stratified analyses. Second, owing to lack of original data, an evaluation of gene--gene, gene--environment, and different polymorphism loci interactions, which may alter cancer risk, could not be carried out in our study. In fact, the study conducted by Yamamoto et al[@b15-ott-9-899] had studied the combined effects of two SNPs of Exo1 on cancer risk. Third, serious confounding bias may exist because we calculated only unadjusted ORs; other risk factors such as age, sex, smoking status, and other variables were not adjusted. A more precise analysis should be conducted if more detailed personal data are available. Fourth, we used only published and English articles, which may bias the results, although the funnel plot and Egger's test did not indicate remarkable publication bias. Despite the limitations, the advantages of this meta-analysis should also be acknowledged. First, the statistical power was significantly increased. Second, the studies included in this meta-analysis were satisfactory and met the inclusion criteria.

In conclusion, the results from this meta-analysis suggest that the *Exo1* Pro757Leu polymorphism contributes to reduced cancer susceptibility, especially in the Asian population, hospital-based studies, and colorectal cancer. However, the Glu589Lys polymorphism was found to be statistically associated with an increased cancer risk in the Asian population, smokers, and hospital-based studies. In addition, no evidence of an association was found between the Glu670Gly polymorphism and cancer risks. In the future, well-designed and population-based studies with larger sample sizes are needed to clarify the association between these polymorphisms and the risk of cancer.
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![Forest plots of ORs with 95% CI for *Exo1* Pro757Leu polymorphism and the risk of cancer observed in subgroup analyses by ethnicity.\
**Notes:** The center of each square represents the OR, the area of the square represents the sample number and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI. (**A**) Dominant model; (**B**) heterozygote comparison.\
**Abbreviations:** OR, odds ratio; 95% CI, 95% confidence interval.](ott-9-899Fig2){#f2-ott-9-899}

![Forest plot of ORs with 95% CI for the *Exo1* Glu589Lys polymorphism and the risk of cancer for the dominant model (Lys/Lys+Glu/Lys vs Glu/Glu) in smokers. **Notes:** The center of each square represents the OR, the area of the square represents the sample number and thus the weight used in the meta-analysis, and the horizontal line indicates the 95% CI. Weights are from random effects analysis.\
**Abbreviations:** OR, odds ratio; 95% CI, 95% confidence interval.](ott-9-899Fig3){#f3-ott-9-899}

![Begg's funnel plots for the *Exo1* polymorphisms and the risk of cancer for the publication bias test.\
**Notes:** Each point represents a separate study for the indicated association. Log (OR); natural logarithm of OR. The horizontal line indicates the effect size. (**A**) Pro757Leu polymorphism; (**B**) Glu589Lys polymorphism; (**C**) Glu670Gly polymorphism.\
**Abbreviation:** OR, odds ratio.](ott-9-899Fig4){#f4-ott-9-899}

###### 

Characteristics of studies included in the meta-analysis

  Study                                    Ethnicity   Region                       SNPs studied    Cancer types     Genotyping                   Control source   Cases/controls
  ---------------------------------------- ----------- ---------------------------- --------------- ---------------- ---------------------------- ---------------- ---------------------------
  Yamamoto et al[@b15-ott-9-899]           Asian       Japan                        757             Colorectal       PCR-RFLP                     PB               102/110
  Zienolddiny et al[@b16-ott-9-899]        Caucasian   Norway                       589             Lung             TaqMan                       PB               256/291
  Kim et al[@b17-ott-9-899]                Asian       Korea                        757             Colorectal       DHPLC                        HB               268/300
  Chang et al[@b18-ott-9-899]              Caucasian   USA                          589, 670        Glioblastoma     Microarray                   PB               112/110
  Jin et al[@b19-ott-9-899]                Asian       People's Republic of China   757, 589, 670   Lung             Illumina                     HB               500/517
  Bau et al[@b20-ott-9-899]                Asian       Taiwan                       757, 589, 670   Gastric          PCR-RFLP                     HB               179/179
  Hsu et al[@b21-ott-9-899]                Asian       Taiwan                       757, 589, 670   Lung             PCR-RFLP                     HB               358/358
  Tsai et al[@b22-ott-9-899]               Asian       Taiwan                       757, 589, 670   Oral             PCR-RFLP                     HB               680/680
  Wang et al[@b23-ott-9-899]               Asian       Taiwan                       757, 589, 670   Breast           PCR-RFLP                     HB               1,272/1,272
  Wang et al[@b24-ott-9-899]               Mixed       Costa Rica                   757             Cervical         TaqMan                       PB               460/431
  Haghighi et al[@b25-ott-9-899]           Asian       Iran                         757             Colorectal       PCR-RFLP                     HB               90/98
  Ibarrola-Villava et al[@b26-ott-9-899]   Caucasian   Spain                        757, 589, 670   Melanoma         Sequenom, TaqMan, Sequenom   HB               684/406, 599/379, 599/379
  Bayram et al[@b27-ott-9-899]             Caucasian   Turkey                       589             Hepatocellular   PCR-RFLP                     HB               224/224
  Luo et al[@b28-ott-9-899]                Asian       People's Republic of China   589             Cervical         PCR-RFLP                     HB               126/278
  Kabzinski et al[@b29-ott-9-899]          Caucasian   Poland                       589             Colorectal       TaqMan                       NA               150/150
  Tang et al[@b30-ott-9-899]               Caucasian   Multiple Regions             589             Pancreatic       Illumina                     Mixed            2,023/2,112

**Abbreviations:** SNP, single nucleotide polymorphism; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; TaqMan, real-time TaqMan analysis; DHPLC, denaturing high-performance liquid chromatography; Sequenom, genotyping was performed using the Sequenom platform; PB, population based; HB, hospital based; NA, not available.

###### 

Genotype distribution of *Exo1* polymorphisms used in this study

  Polymorphism   Disease          First author                             Ethnicity   Sample size (case/control)   Case   Control   HWE   MAF                       
  -------------- ---------------- ---------------------------------------- ----------- ---------------------------- ------ --------- ----- ----- ----- ----- ------- -------
  Pro757Leu      Colorectal       Yamamoto et al[@b15-ott-9-899]           Asian       102/110                      35     53        14    36    47    27    0.143   0.459
                 Colorectal       Kim et al[@b17-ott-9-899]                Asian       268/300                      108    125       35    99    163   38    0.021   0.398
                 Lung             Jin et al[@b19-ott-9-899]                Asian       500/517                      --     --        --    --    --    --    --      0.409
                 Gastric          Bau et al[@b20-ott-9-899]                Asian       179/179                      62     78        39    56    84    39    0.479   0.453
                 Lung             Hsu et al[@b21-ott-9-899]                Asian       358/358                      124    156       78    112   167   79    0.264   0.454
                 Oral             Tsai et al[@b22-ott-9-899]               Asian       680/680                      235    297       148   214   313   153   0.061   0.455
                 Breast           Wang et al[@b23-ott-9-899]               Asian       1,272/1,272                  433    563       276   402   596   274   0.057   0.450
                 Cervical         Wang et al[@b24-ott-9-899]               Mixed       460/431                      175    214       71    169   217   45    0.042   0.356
                 Colorectal       Haghighi et al[@b25-ott-9-899]           Asian       90/98                        60     28        2     51    37    10    0.402   0.291
                 Melanoma         Ibarrola-Villava et al[@b26-ott-9-899]   Caucasian   684/406                      485    186       13    297   99    10    0.611   0.147
  Glu589Lys      Lung             Zienolddiny et al[@b16-ott-9-899]        Caucasian   256/291                      115    106       35    116   145   30    0.117   0.352
                 Glioblastoma     Chang et al[@b18-ott-9-899]              Caucasian   112/110                      55     42        15    29    59    22    0.419   0.468
                 Lung             Jin et al[@b19-ott-9-899]                Asian       500/517                      304    172       24    355   138   24    0.030   0.180
                 Gastric          Bau et al[@b20-ott-9-899]                Asian       179/179                      103    64        12    125   49    5     0.940   0.165
                 Lung             Hsu et al[@b21-ott-9-899]                Asian       358/358                      214    125       19    251   97    10    0.865   0.163
                 Oral             Tsai et al[@b22-ott-9-899]               Asian       680/680                      391    244       45    482   183   15    0.626   0.157
                 Breast           Wang et al[@b23-ott-9-899]               Asian       1,272/1,272                  794    421       57    898   341   33    0.926   0.160
                 Melanoma         Ibarrola-Villava et al[@b26-ott-9-899]   Caucasian   599/379                      234    282       83    136   175   68    0.373   0.410
                 Hepatocellular   Bayram et al[@b27-ott-9-899]             Caucasian   224/224                      95     94        35    99    108   17    0.089   0.317
                 Cervical         Luo et al[@b28-ott-9-899]                Asian       126/278                      73     48        5     196   77    5     0.412   0.156
                 Colorectal       Kabzinski et al[@b29-ott-9-899]          Caucasian   150/150                      22     95        33    49    62    39    0.038   0.467
                 Pancreatic       Tang et al[@b30-ott-9-899]               Caucasian   2,023/2,112                  827    910       286   815   993   304   0.956   0.379
  Glu670Gly      Glioblastoma     Chang et al[@b18-ott-9-899]              Caucasian   112/111                      44     57        11    46    47    18    0.314   0.374
                 Lung             Jin et al[@b19-ott-9-899]                Asian       500/517                      --     --        --    --    --    --    --      0.181
                 Gastric          Bau et al[@b20-ott-9-899]                Asian       179/179                      131    39        9     135   36    8     0.011   0.145
                 Lung             Hsu et al[@b21-ott-9-899]                Asian       358/358                      262    78        18    269   73    16    0.000   0.147
                 Oral             Tsai et al[@b22-ott-9-899]               Asian       680/680                      497    148       35    511   138   31    0.000   0.147
                 Breast           Wang et al[@b23-ott-9-899]               Asian       1,272/1,272                  941    267       64    958   255   59    0.000   0.147
                 Melanoma         Ibarrola-Villava et al[@b26-ott-9-899]   Caucasian   599/379                      239    293       67    160   171   48    0.826   0.352

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency; A, the major allele; a, the minor allele.

###### 

Results of meta-analysis for *Exo1* polymorphisms and the risk of cancer

  Genetic model   Recessive model    Dominant model               Homozygote                   Heterozygote         Additive model                                                                                                                                                           
  --------------- ------------------ ---------------------------- ---------------------------- -------------------- ---------------------- ------------- -------- ---------------------- ------------- -------- ---------------------- ------------- -------- ---------------------- ------- ------
  Total           10 (4,593/4,351)   0.995 (0.883--1.122)         0.098                        40.4                 0.902 (0.821--0.991)   0.419         1.8      0.920 (0.805--1.053)   0.154                  0.894 (0.809--0.988)   0.530         0.0      0.960 (0.902--1.020)   0.188   27.9
  Ethnicity                                                                                                                                                                                                                                                                                  
   Asian          8 (3,449/3,514)    0.955 (0.842--1.084)         0.252                        23.2                 0.852 (0.765--0.949)   0.744         0.0      0.872 (0.755--1.007)   0.410         1.9      0.847 (0.755--0.951)   0.809         0.0      0.932 (0.871--0.997)   0.341   11.4
   Caucasian      1 (684/406)        0.767 (0.333--1.766)         --                           --                   1.118 (0.850--1.471)   --            --       0.796 (0.345--1.838)   --            --       1.151 (0.867--1.527)   --            --       1.068 (0.837--1.362)   --      --
   Mixed          1 (460/431)        1.566 (1.050--2.334)         --                           --                   1.050 (0.802--1.376)   --            --       1.524 (0.992--2.340)   --            --       0.952 (0.717--1.264)   --            --       1.141 (0.941--1.383)   --      --
  CS                                                                                                                                                                                                                                                                                         
   PB             2 (562/540)        0.910 (0.292--2.838)         0.005                        87.2                 1.028 (0.805--1.312)   0.708         0.0      0.953 (0.343--2.651)   0.023         80.7     0.986 (0.763--1.275)   0.565         0.0      1.056 (0.890--1.255)   0.080   67.5
   HB             8 (4,031/3,811)    0.972 (0.856--1.105)         0.600                        0.0                  0.882 (0.797--0.977)   0.347         10.8     0.884 (0.766--1.022)   0.592         0.0      0.878 (0.788--0.979)   0.417         0.9      0.946 (0.886--1.010)   0.330   12.8
  Cancer                                                                                                                                                                                                                                                                                     
   Colorectal     3 (728/768)        0.717 (0.489--1.050)         0.053                        66.0                 0.724 (0.557--0.942)   0.435         0        0.633 (0.417--0.961)   0.135         50.2     0.766 (0.581--1.009)   0.315         13.5     0.782 (0.648--0.943)   0.208   36.2
   Lung           2 (858/875)        0.984 (0.690--1.402)         --                           --                   0.859 (0.629--1.174)   --            --       0.892 (0.595--1.336)   --            --       0.844 (0.603--1.181)   --            --       0.988 (0.863--1.130)   0.450   0.0
  HWE                                                                                                                                                                                                                                                                                        
   Yes            7 (3,365/3,103)    0.945 (0.830--1.076)         0.240                        24.8                 0.900 (0.810--0.999)   0.488         0.0      0.872 (0.753--1.010)   0.407         2.4      0.906 (0.810--1.013)   0.532         0.0      0.933 (0.868--1.004)   0.283   19.3
   No             3 (1,228/1,248)    1.331 (0.978--1.812)         0.201                        38.8                 0.914 (0.739--1.129)   0.102         62.7     1.210 (0.868--1.687)   0.091         64.9     0.847 (0.679--1.058)   0.193         41.0     1.027 (0.916--1.151)   0.207   36.5
                                                                                                                                                                                                                                                                                             
  Glu589Lys       n                  Lys/Lys vs Glu/Lys+Glu/Glu   Lys/Lys+Glu/Lys vs Glu/Glu   Lys/Lys vs Glu/Glu   Lys/Lys vs Glu/Glu     Lys vs Glu                                                                                                                                        
  OR (95% CI)     *P*~h~             *I*^2^ (%)                   OR (95% CI)                  *P*~h~               *I*^2^ (%)             OR (95% CI)   *P*~h~   *I*^2^ (%)             OR (95% CI)   *P*~h~   *I*^2^ (%)             OR (95% CI)   *P*~h~   *I*^2^ (%)                     
                                                                                                                                                                                                                                                                                             
  Total           12 (6,479/6,550)   1.320 (0.999--1.744)         0.000                        71.6                 1.237 (0.995--1.538)   0.000         86.6     1.447 (1.028--2.035)   0.000         79.0     1.208 (0.974--1.498)   0.000         84.8     1.200 (1.014--1.421)   0.000   86.7
  Ethnicity                                                                                                                                                                                                                                                                                  
   Asian          6 (3,115/3,214)    1.876 (1.444--2.436)         0.194                        32.2                 1.555 (1.401--1.726)   0.650         0.0      2.133 (1.639--2.777)   0.161         36.8     1.495 (1.341--1.666)   0.903         0.0      1.487 (1.361--1.625)   0.330   13.3
   Caucasian      6 (3,364/3,266)    1.000 (0.751--1.332)         0.019                        62.9                 0.936 (0.697--1.257)   0.000         81.0     1.016 (0.701--1.475)   0.002         73.1     0.931 (0.673--1.288)   0.000         82.5     0.954 (0.807--1.128)   0.004   71.0
  CS                                                                                                                                                                                                                                                                                         
   PB             2 (368/401)        1.042 (0.687--1.580)         0.076                        68.2                 0.568 (0.264--1.221)   0.019         81.7     0.674 (0.211--2.151)   0.016         82.6     0.616 (0.453--0.836)   0.058         72.1     0.734 (0.415--1.297)   0.013   83.8
   HB             8 (5,961/5,999)    1.683 (1.097--2.581)         0.000                        74.0                 1.405 (1.180--1.674)   0.004         66.9     1.848 (1.164--2.934)   0.000         76.5     1.356 (1.161--1.583)   0.033         54.0     1.366 (1.144--1.632)   0.000   78.9
  Cancer                                                                                                                                                                                                                                                                                     
   Lung           3 (1,114/1,166)    1.338 (0.948--1.888)         0.436                        0.0                  1.231 (0.848--1.787)   0.010         78.2     1.346 (0.944--1.921)   0.362         1.5      1.188 (0.777--1.816)   0.004         81.5     1.230 (0.961--1.574)   0.046   67.5
  HWE                                                                                                                                                                                                                                                                                        
   Yes            10 (5,829/5,883)   1.444 (1.039--2.005)         0.000                        75.7                 1.149 (0.908--1.454)   0.000         87.2     1.451 (0.975--2.158)   0.000         82.1     1.104 (0.884--1.378)   0.000         84.0     1.181 (0.971--1.436)   0.000   88.8
   No             2 (650/667)        0.902 (0.610--1.334)         0.525                        0.0                  1.904 (0.972--3.727)   0.029         78.9     1.434 (0.901--2.282)   0.298         7.8      2.135 (0.930--4.901)   0.011         84.6     1.298 (1.084--1.554)   0.884   0.0
                                                                                                                                                                                                                                                                                             
  Glu670Gly       n                  Glu/Glu vs Gly/Glu+Gly/Gly   Glu/Glu vs Gly/Glu+Gly/Gly   Glu/Glu vs Gly/Gly   Gly/Glu vs Gly/Gly     Glu vs Gly                                                                                                                                        
  OR (95% CI)     *P*~h~             *I*^2^ (%)                   OR (95% CI)                  *P*~h~               *I*^2^ (%)             OR (95% CI)   *P*~h~   *I*^2^ (%)             OR (95% CI)   *P*~h~   *I*^2^ (%)             OR (95% CI)   *P*~h~   *I*^2^ (%)                     
                                                                                                                                                                                                                                                                                             
  Total           7 (3,700/3,496)    0.989 (0.802--1.219)         0.683                        0.0                  1.094 (0.978--1.224)   1.000         0.0      1.037 (0.837--1.286)   0.861         0.0      1.104 (0.978--1.245)   0.994         0.0      1.057 (0.971--1.151)   0.982   0.0
  Ethnicity                                                                                                                                                                                                                                                                                  
   Asian          5 (2,989/3,006)    1.111 (0.857--1.440)         0.999                        0.0                  1.093 (0.962--1.241)   0.994         0.0      1.131 (0.871--1.468)   0.998         0.0      1.084 (0.944--1.244)   0.996         0.0      1.078 (0.977--1.189)   0.994   0.0
   Caucasian      2 (711/490)        0.796 (0.559--1.132)         0.341                        0.0                  1.099 (0.869--1.390)   0.984         0.0      0.867 (0.595--1.263)   0.435         0.0      1.169 (0.913--1.497)   0.755         0.0      0.997 (0.840--1.182)   0.617   0.0
  CS                                                                                                                                                                                                                                                                                         
   PB             1 (112/111)        0.563 (0.253--1.254)         --                           --                   1.094 (0.640--1.868)   --            --       0.639 (0.271--1.504)   --            --       1.268 (0.720--2.232)   --            --       0.912 (0.620--1.342)   --      --
   HB             6 (3,588/3,385)    1.032 (0.830--1.282)         0.900                        0.0                  1.094 (0.976--1.227)   0.999         0.0      1.072 (0.859--1.339)   0.963         0.0      1.096 (0.969--1.240)   0.996         0.0      1.065 (0.976--1.162)   0.992   0.0
  Cancer                                                                                                                                                                                                                                                                                     
   Lung           2 (858/875)        1.132 (0.568--2.256)         --                           --                   1.107 (0.792--1.548)   --            --       1.155 (0.577--2.313)   --            --       1.097 (0.764--1.575)   --            --       1.062 (0.890--1.267)   0.748   0.0

**Notes:** Random-effects model was used when *P*-value for heterogeneity test \<0.05; otherwise, fixed-model was used.

**Abbreviations:** CS, control source; PB, population based; HB, hospital based; *P*~h~, *P*-values for heterogeneity from *Q*-test; HWE, Hardy--Weinberg equilibrium; OR, odds ratio; 95% CI, 95% confidence interval; n, number.

###### 

Results of stratified analysis by smoking status for *Exo1* Glu589Lys polymorphism in dominant model (Lys/Lys+Glu/Lys vs Glu/Glu)

  Smoking      Number of studies (n of cases/n of controls)   Lys/Lys+Glu/Lys vs Glu/Glu           
  ------------ ---------------------------------------------- ---------------------------- ------- ------
  Smokers      4 (1,268/1,151)                                1.866 (1.384--2.515)         0.038   64.5
  Nonsmokers   4 (449/583)                                    1.114 (0.862--1.440)         0.148   43.9

**Notes:** Random-effects model was used when *P*-value for heterogeneity test \<0.05; otherwise, fixed-model was used.

**Abbreviations:** *P*~h~, *P*-values for heterogeneity from *Q*-test; OR, odds ratio; 95% CI, 95% confidence interval; n, number.

###### 

Univariate meta-regression analysis for heterogeneity of Glu589Lys polymorphism

  Covariates   Recessive model   Dominant model   Homozygote   Heterozygote   Additive model                                     
  ------------ ----------------- ---------------- ------------ -------------- ---------------- ------- -------- ------- -------- -------
  Ethnicity    −0.638            0.029            −0.535       0.035          −0.768           0.032   −0.501   0.111   −0.456   0.003
  Year         −0.044            0.493            0.052        0.408          0.015            0.859   0.063    0.330   0.007    0.867
  SS           0.016             0.961            0.087        0.777          0.000            0.999   0.109    0.730   0.082    0.690
  HWE          −0.464            0.275            0.506        0.205          0.008            0.989   0.636    0.114   0.099    0.718

**Abbreviations:** SS, sample size; HWE, Hardy--Weinberg equilibrium.
